DavidE.KozonoMD(He/Him)
Radiation Oncology • Boston, MAThoracic Cancer
Asst. Professor, Radiation Oncology-Brigham & Women's/Children's/Dana-Farber Cancer Inst, Harvard Med School
Dr. Kozono is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Bwh Radiation Oncology Asb1-L2
Boston, MA 02115Phone+1 617-632-3591
Summary
- Dr. David Kozono, based in Boston, MA, specializes in Radiation Oncology with a particular focus on Thoracic Cancer. A graduate of Johns Hopkins University School of Medicine in 2005, he subsequently completed his internship and residency at Brigham and Women's Hospital, Massachusetts General Hospital, and Harvard Medical School. Dr. Kozono's expertise lies in the treatment of lung cancer and he has contributed to several publications in his field, including lung cancer clinical trials and translational research. He is currently involved in multiple clinical trials, such as MCT for the Harvard/UCSF ROBIN Center. Dr. Kozono received the Meaningful Use Stage 1 Certification from Centers for Medicare & Medicaid Services in 2012.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2006 - 2010- Brigham and Women's HospitalInternship, Internal Medicine, 2005 - 2006
Johns Hopkins University School of MedicineClass of 2005
Certifications & Licensure
MA State Medical License 2007 - 2025- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
- Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) Start of enrollment: 2019 Jul 26
- MCT for the Harvard/UCSF ROBIN Center Start of enrollment: 2023 Sep 19
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsLung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).David Kozono, Xing Hua, Michael C Wu, Khaled A Tolba, Saiama N Waqar
Journal of Thoracic Oncology. 2024-12-01 - An open annotated dataset and baseline machine learning model for segmentation of vertebrae with metastatic bone lesions from CT.Nazim Haouchine, David B Hackney, Steve D Pieper, William M Wells, Malika Sanhinova
Medrxiv. 2024-11-12 - 1 citationsIdentify Non-mutational p53 Functional Deficiency in Human Cancers.Qianpeng Li, Yang Zhang, Sicheng Luo, Zhang Zhang, Ann L Oberg
Genomics, Proteomics & Bioinformatics. 2024-09-26
Journal Articles
- Association of Left Anterior Descending Coronary Artery Radiation Dose with Major Adverse Cardiac Events and Mortality in Patients with Non–Small Cell Lung CancerKatelyn M Atkins, David E Kozono, Elizabeth H Baldini, Raymond H Mak, JAMA Oncology
Press Mentions
Using the Biobank to Advance Radiation Oncology ResearchSeptember 24th, 2024- Making Radiation Therapy Safer for the HeartSeptember 13th, 2024
- Lung-MAP Translational Discoveries Shared at 2020 World Conference on Lung CancerJanuary 27th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
